rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AURA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      OXB partners with Aura Biosciences for phase 3 drug manufacturing
      Nov 17Investing.comAURA
      Oxford Biomedica Confirms Manufacturing Partnership with Aura Biosciences for Phase 3 Cancer Treatment

      Oxford Biomedica plc (LSE:OXB) confirmed a manufacturing and supply partnership with Aura Biosciences (NASDAQ:AURA) to support Phase 3 development and preparations for potential commercial production of an experimental treatment for ocular cancers. The agreement, established earlier in 2026, covers development and manufacturing activities for Aura’s lead virus-like drug conjugate (VDC) candidate, belzupacap sarotalocan (bel-sar).

      Nov 17Yahoo FinanceAURA
      Aura Biosciences CMO Janet Hopkins sells $119,166 in shares
      Nov 17Investing.comAURA
      Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to Trade
      Nov 11Yahoo FinanceAURA
      Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
      Nov 9Yahoo FinanceAURA
      Aura Biosciences to Participate in Upcoming Investor Conference
      Nov 3Yahoo FinanceAURA
      Aura Biosciences: A Pivotal Trial Engineered With Room To Spare (NASDAQ:AURA)

      Aura Biosciences offers a fully funded ocular oncology play with a Phase 3 upside and limited financing risk. Click to read more on AURA here.

      Oct 31Seeking AlphaAURA
      Aura Biosciences at Morgan Stanley conference: bel-sar takes center stage
      Sep 16Investing.comAURAMS
      Aura Biosciences to Participate in Upcoming Investor Conference

      BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.Fireside Chat at 2:35 p.m. ET The live webcast of the fireside chat will

      Sep 2Yahoo FinanceAURA
      Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new C

      Sep 1Yahoo FinanceAURA

      This is the newest page. Registered accounts read further back.